Abstract
Introduction
To investigate the effect of zoledronic acid on periprosthetic bone mineral density (BMD) and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.
Methods
From November 2015 to April 2016, 40 female patients who met the inclusion criteria were randomized into two groups: a control group (calcium + calcitriol) and a zoledronic acid group (calcium + calcitriol + zoledronic acid). At 1 week and 3, 6, and 12 months after operation, BMD was obtained through dual-energy X-ray absorptiometry (DEXA). At pre-operation and at 3, 6, and 12 months after the operation, levels of bone metabolism markers were obtained by serum examination.
Results
Loss of BMD was significantly more pronounced in the control group than in the ZOL group in zones 1, 4, 6, and 7 at 6 months and in zones 1, 2, 4, 6, and 7 at 12 months after the operation. The levels of bone-resorption marker (β-CTX) were significantly lower in the ZOL group than in the control group at 3, 6, and 12 months after operation. The levels of bone-formation marker (TP1NP) performed statistically differences only at 12 months after the operation in these two groups.
Conclusions
Receiving an intravenous infusion of 5 mg zoledronic acid after THA can effectively reduce periprosthetic BMD loss and improve bone remodeling in females with postmenopausal osteoporosis.
Summary
Zoledronic acid significantly inhibited bone mass loss in zones 1, 2, 4, 6, and 7 after THA and inhibited bone-resorption marker (β-CTX) to improve bone remodeling. Zoledronic acid treatment is potentially important for patients with osteoporosis after THA.
Similar content being viewed by others
References
Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733
Godoy Monzón D, Iserson KV, Jauregui J, Musso C, Piccaluga F, Buttaro M (2014) Total hip arthroplasty for hip fractures: 5-year follow-up of functional outcomes in the oldest independent old and very old patients. Geriatr Orthop Surg Rehabil 5:3–8
Venesmaa PK, Kröger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhava EM (2001) Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy X-ray absorptiometry – a 3-year follow-up study. J Bone Miner Res 16:1056–1061
Bodén HS, Sköldenberg OG, Salemyr MO, Lundberg HJ, Adolphson PY (2006) Continuous bone loss around a tapered uncemented femoral stem: a long-term evaluation with DEXA. Acta Orthop 77:877–885
Furnes O, Lie SA, Espehaug B, Vollset SE, Engesaeter LB, Havelin LI (2001) Hip disease and the prognosis of total hip replacements. A review of 53,698 primary total hip replacements reported to the Norwegian Arthroplasty Register 1987–99. J Bone Joint Surg (Br) 83:579–586
Nguyen ND, Eisman JA, Nguyen TV (2006) Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res 21:340–349
Knusten AR, Ebramzadeh E, Longjohn DB, Sangiorgio SN (2014) Systematic analysis of bisphosphonate intervention on periprosthetic BMD as a function of stem design. J Arthroplast 29:1292–1297
Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M (2009) Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res 27:183–188
Scott DF, Woltz JN, Smith RR (2013) Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: preliminary results of a prospective randomized trial. J Arthroplast 28:671–675
Khatod M, Inacio MC, Dell RM, Bini SA, Paxton EW, Namba RS (2015) Association of bisphosphonate use and risk of revision after THA: outcomes from a US total joint replacement registry. Clin Orthop Relat Res 473:3412–3420
Bell KJ, Hayen A, Glasziou P, Irwig L, Eastell R, Harrison SL, Black DM, Bauer DC (2016) Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis: secondary analysis of randomized controlled trial data. J Bone Miner Res 31:1767–1773
Aro HT, Alm JJ, Moritz N, Mäkinen TJ, Lankinen P (2012) Low BMD affects initial stability and delays stem osseointegration in cementless total hip arthroplasty in women: a 2-year RSA study of 39 patients. Acta Orthop 83:107–114
Muratore M, Quarta E, Quarta L, Calcagnile F, Grimaldi A, Orgiani MA, Marsilio A, Rollo G (2012) Ibandronate and cementless total hip arthroplasty: densitometric measurement of periprosthetic bone mass and new therapeutic approach to the prevention of aseptic loosening. Clin Cases Miner Bone Metab 9:50–55
Lin T, Yan SG, Cai XZ, Ying ZM (2012) Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int 23:1823–1834
Zhao X, Hu D, Qin J, Mohanan R, Chen L (2015) Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis. J Orthop Surg Res 10:65
Chao M, Hua Q, Yingfeng Z (2013) Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pak J Med Sci 29:1381–1384
Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interaction with hydroxyapatite. Bone 38:617–627
Kobayashi N, Inaba Y, Uchiyama M, Ike H, Kubota S, Saito T (2016) Teriparatide versus alendronate for the preservation of bone mineral density after Total hip arthroplasty - a randomized controlled trial. J Arthroplast 31:333–338
Tankó LB, Mouritzen U, Lehmann HJ, Warming L, Moelgaard A, Christgau S, Qvist P, Baumann M, Wieczorek L, Hoyle N, Christiansen C (2003) Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 32:687–693
Slovik DM, Adams JS, Neer RM, Holick MF, Potts JT Jr (1981) Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients. N Engl J Med 305:372–374
Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH) D level needed to maintain a favorable bisphosphonate response is ≥33ng/ml. Osteoporos Int 23:2479–2487
Bjork A, Mellstrom D, Ohlsson C, Karlsson M, Mallmin H, Johansson G, Ljunggren O, Kindmark A (2018) Haplotypes in the CYP2R1 gene are associated with levels of 25(OH) D and bone mineral density, but not with other markers of bone metabolism. PLoS One 13:12
Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357–362
Friedl G, Radl R, Stihsen C, Rehak P, Aigner R, Windhager R (2009) The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am 91:274–281
Nagae M, Hiraga T, Yoneda T (2007) Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab 25:99–104
Woo SB, Hellstein JW, Kalmar JR (2006) Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761
Funding
This work was supported by the National High Technology Research and Development Program of China (2015AA020316), Jiangsu Province’s Key Medical center, Jiangsu Provincial Special Program of Medical Science (BL2012004), Natural Science Foundation of Jiangsu Province (BK20180001), the Jiangsu Provincial Medical Youth Talent (QNRC2016751), and the National Nature Science Foundation of China (grant nos. 81873990, 81873991, 81672238, 81572183, 81472077, 81372018).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflicts of interest
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhou, W., Liu, Y., Guo, X. et al. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis. Osteoporos Int 30, 1581–1589 (2019). https://doi.org/10.1007/s00198-019-05005-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-019-05005-7